Interim estimates of 2017-18 seasonal influenza vaccine effectiveness - United States, February 2018

Morbidity and Mortality Weekly Report

Volumn 67, Issue 6, 2018, Pages 180-185

  Flannery, Brendan ^a   Chung, Jessie R ^a   Belongia, Edward A ^b   McLean, Huong Q ^b   Gaglani, Manjusha ^c   Murthy, Kempapura ^c   Zimmerman, Richard K ^d   Nowalk, Mary Patricia ^d   Jackson, Michael L ^e   Jackson, Lisa A ^e   Monto, Arnold S ^f   Martin, Emily T ^f   Foust, Angie ^a   Sessions, Wendy ^a   Berman, La Shondra ^a   Barnes, John R ^a   Spencer, Sarah ^a   Fry, Alicia M ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b MARSHFIELD CLINIC   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e KAISER PERMANENTE   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HEALTH SURVEY; HUMAN; IMMUNOLOGY; INFANT; INFLUENZA; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; PRESCHOOL CHILD; SEASON; UNITED STATES; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; SEASONS; UNITED STATES; YOUNG ADULT;

EID: 85042062485     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: 10.15585/mmwr.mm6706a2     Document Type: Article

References (10)

1. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices-United States, 2017-18 influenza season. MMWR Recomm Rep 2017;66(No. RR-2). https://doi.org/10.15585/mmwr.rr6602a1
2. Jackson ML, Chung JR, Jackson LA, et al. Influenza vaccine effectiveness in the United States during the 2015-2016 season. N Engl J Med 2017;377:534-43. https://doi.org/10.1056/NEJMoa1700153
3. Budd AP, Wentworth DE, Blanton L, et al. Update: influenza activity-United States, October 1, 2017-February 3, 2018. MMWR Morb Mortal Wkly Rep 2018;67:169-79.
4. Skowronski DM, Chambers C, De Serres G, et al. Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018. Euro Surveill 2018;23. https://doi.org/10.2807/1560-7917.ES.2018.23.5.18-00035
5. Sullivan SG, Chilver MB, Carville KS, et al. Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017. Euro Surveill 2017;22. https://doi.org/10.2807/1560-7917.ES.2017.22.43.17-00707
6. Flannery B, Chung JR, Thaker SN, et al. Interim estimates of 2016-17 seasonal influenza vaccine effectiveness-United States, February 2017. MMWR Morb Mortal Wkly Rep 2017;66:167-71. https://doi.org/10.15585/mmwr.mm6606a3
7. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis 2016;16:942-51. https://doi.org/10.1016/S1473-3099(16)00129-8
8. Zost SJ, Parkhouse K, Gumina ME, et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci U S A 2017;114:12578-83. https://doi.org/10.1073/pnas.1712377114
9. Wu NC, Zost SJ, Thompson AJ, et al. A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog 2017;13:e1006682. https://doi.org/10.1371/journal.ppat.1006682
10. Fry AM, Kim IK, Reed C, et al. Modeling the effect of different vaccine effectiveness estimates on the number of vaccine-prevented influenza-associated hospitalizations in older adults. Clin Infect Dis 2014;59:406-9. https://doi.org/10.1093/cid/ciu328